THIOTEPA FOR INJECTION USP POWDER FOR SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

THIOTEPA

제공처:

STERIMAX INC

ATC 코드:

L01AC01

INN (International Name):

THIOTEPA

복용량:

15MG

약제 형태:

POWDER FOR SOLUTION

구성:

THIOTEPA 15MG

관리 경로:

INTRAVENOUS

패키지 단위:

15G/50G

처방전 유형:

Prescription

제품 요약:

Active ingredient group (AIG) number: 0107649001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2022-05-18

제품 특성 요약

_Thiotepa for Injection USP _
_Page 1 of 46 _
“Thiotepa for Injection USP is indicated:
_- in combination with other chemotherapeutic products as part of a
high-dose chemotherapy _
_(HDCT) consolidation regimen followed by autologous stem cell
transplantation (ASCT) for _
_adult patients with central nervous system (CNS) lymphoma_
_ _
and has been issued marketing authorization with conditions. Patients
should be advised of
the nature of the authorization. For further information for Thiotepa
for Injection USP please
refer to Health Canada’s Notice of Compliance with conditions - drug
products web site:
https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-
products/notice-compliance/conditions.html. Note that trials to verify
the clinical benefit of
the medicinal ingredient in Thiotepa for Injection USP are being
carried out by the
manufacturer of the Canadian Reference Product.”
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
THIOTEPA FOR INJECTION USP
Lyophilised powder for solution upon reconstitution and dilution,
15 mg / vial and 100 mg / vial, intravenous
USP
Antineoplastic Agent
ATC code: L01AC01
SteriMax Inc.
2770 Portland Drive
Oakville, ON, Canada
L6H 6R4
Submission Control Number: 272936
Date of Initial Authorization:
May 18, 2022
Date of Revision:
October 4, 2023
_Thiotepa for Injection USP _
_Page 2 of 46 _
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
5
1
INDICATIONS
...............................................................................................................
5
1.1
Pediatrics
..